Objective: To investigate the expression of CD34 and α-SMA in stromal fibroblasts of benign and malignant breast lesions and their clinical significances.
Methods: The expression of CD34 and α-SMA in stromal fibroblasts of tissues from 100 cases of benign breast lesions， 32 cases of ductal carcinoma in situ (DCIS) and 150 cases of breast cancer were detected by immunohistochemical staining. The correlation of CD34 with α-SMA was analyzed.
Results: The positive rate of CD34 and α-SMA of stromal fibroblasts was 90% (90/100) and 49% (49/100) in benign breast lesion， 91% (29/32) and 81% (26/32) in DCIS， and 4% (6/150) and 99% (148/150) in cancer， respectively. Among the three tissues studied， the expression of CD34 in breast cancer was significantly lower than that of benign breast lesion and DCIS (both P<0.05)， and had no difference between benign breast lesion and DCIS (P>0.05). The expression of α-SMA was all significantly different among the three tissues (P<0.05). No correlation was noted between the expression of CD34 and α-SMA in the three tissues studied (P>0.05).
Conclusions: CD34 and α-SMA are sensitive indexes for stromal fibroblasts variations in breast gland， and their combination detection might be helpful for assessing the properties of breast lesions.